New drug shows promise for rare Skin-Hardening disease
NCT ID NCT05214794
First seen Feb 17, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This early study tested a drug called nemolizumab in 6 people with systemic sclerosis, a rare disease that causes skin to harden and tighten. The main goal was to see if the drug could reduce skin thickness over 24 weeks, and to check for side effects. Researchers also looked at how the drug moves through the body and whether benefits last up to 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Tokyo Hospital
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.